60,028 Shares in Denali Therapeutics Inc. $DNLI Acquired by Jupiter Topco LLC

Jupiter Topco LLC bought a new stake in Denali Therapeutics Inc. (NASDAQ:DNLI) in the second quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund bought 60,028 shares of the company’s stock, valued at approximately $1,544,000.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Bank of America Corp DE raised its position in Denali Therapeutics by 21.7% in the first quarter. Bank of America Corp DE now owns 1,134,183 shares of the company’s stock valued at $21,776,000 after purchasing an additional 202,039 shares during the period. Great Lakes Advisors LLC purchased a new position in Denali Therapeutics in the 2nd quarter worth approximately $3,731,000. E. Ohman J or Asset Management AB purchased a new position in Denali Therapeutics in the 2nd quarter worth approximately $4,115,000. Sei Investments Co. acquired a new stake in Denali Therapeutics in the first quarter valued at approximately $1,003,000. Finally, UBS Group AG grew its position in Denali Therapeutics by 19.5% in the fourth quarter. UBS Group AG now owns 2,404,704 shares of the company’s stock valued at $39,702,000 after acquiring an additional 392,351 shares in the last quarter. Institutional investors and hedge funds own 92.92% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research firms recently issued reports on DNLI. UBS Group lifted their price target on shares of Denali Therapeutics from $25.00 to $34.00 and gave the stock a “buy” rating in a research note on Friday, August 7th. Wedbush reissued an “outperform” rating and issued a $26.00 price objective on shares of Denali Therapeutics in a research report on Monday, July 13th. Deutsche Bank Aktiengesellschaft lifted their target price on Denali Therapeutics from $31.00 to $35.00 and gave the stock a “buy” rating in a research report on Thursday, July 16th. B. Riley Financial boosted their price target on Denali Therapeutics from $30.00 to $35.00 and gave the stock a “buy” rating in a research note on Tuesday, August 25th. Finally, Morgan Stanley increased their price target on Denali Therapeutics from $35.00 to $36.00 and gave the company an “overweight” rating in a report on Thursday, July 23rd. Fourteen analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $35.85.

Denali Therapeutics Price Performance

DNLI opened at $22.28 on Friday. The company has a quick ratio of 8.32, a current ratio of 8.37 and a debt-to-equity ratio of 0.01. The company’s 50-day moving average price is $24.44 and its 200 day moving average price is $21.83. Denali Therapeutics Inc. has a fifty-two week low of $12.58 and a fifty-two week high of $27.30. The firm has a market cap of $3.56 billion, a price-to-earnings ratio of -7.85 and a beta of 1.01.

Denali Therapeutics (NASDAQ:DNLI) last issued its earnings results on Thursday, August 6th. The company reported ($0.68) EPS for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.17). The business had revenue of $3.60 million during the quarter, compared to the consensus estimate of $2.15 million. During the same period in the prior year, the firm posted ($0.72) EPS. As a group, sell-side analysts expect that Denali Therapeutics Inc. will post -2.67 earnings per share for the current year.

Insider Activity

In related news, insider Alexander O. Schuth sold 2,768 shares of the business’s stock in a transaction that occurred on Tuesday, September 1st. The stock was sold at an average price of $23.44, for a total transaction of $64,881.92. Following the completion of the transaction, the insider owned 278,995 shares in the company, valued at $6,539,642.80. The trade was a 0.98% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Company insiders own 9.70% of the company’s stock.

About Denali Therapeutics

Denali Therapeutics is a clinical‐stage biopharmaceutical company focused on developing therapies for neurodegenerative diseases. The company’s research leverages a proprietary Blood–Brain Barrier Transport Vehicle (TV) platform designed to enable large molecules, including antibodies and enzymes, to penetrate the central nervous system. Denali’s approach includes small molecules, monoclonal antibodies and gene therapy candidates aimed at key drivers of disorders such as Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral sclerosis (ALS) and frontotemporal dementia.

Among Denali’s lead programs is an orally delivered leucine‐rich repeat kinase 2 (LRRK2) inhibitor for Parkinson’s disease, and an anti‐TREM2 antibody designed to modulate microglial activity in Alzheimer’s patients.